MetaMed AI Cancer Detection Scam: Claiming AI diagnoses cancer, charging high fees to send fake reports

Who Gets Targeted

Victims are primarily cancer high-risk groups, middle-aged and elderly chronic disease patients, and their families, who crave 'faster and more accurate' testing methods due to extreme anxiety over illness. Scammers use terms like 'AI technology' and 'nanodetection' for packaging, and forge 'FDA certification' and doctor endorsements to make people lacking medical common sense believe it. Many still hold out hope after checkups at regular hospitals, willing to spend thousands of dollars to buy 'second opinions,' ultimately receiving unsigned, unnumbered templated reports that not only result in financial loss but also delay real diagnosis and treatment.

骗局怎么运作

• Acquiring leads through advertising: Scammers place ads on social platforms and search engines promising 'AI early cancer screening with 99% accuracy,' with pitches emphasizing 'one drop of blood detects ten types of cancer.' Clicking leads to a high-simulation official website displaying forged expert team photos and academic papers to project a professional image. The purpose of this stage is to collect sensitive patient information such as name, phone number, and medical history to pave the way for precise subsequent harvesting.
• Questionnaire and pitch harvesting: Customer service guides victims through phone or online chat to fill out a multi-page 'AI health assessment questionnaire,' continuously generating pressure such as 'your risk score is already higher than 90% of the population.' They then offer a 'limited-time discount' of $2,980 (down from an original price of $9,800), demanding immediate payment or else 'the system will delete the data,' leveraging fear to drive sales.
• Forged report generation: After receiving the payment, the company actually performs no laboratory testing whatsoever, instead inputting the patient's questionnaire into a generative AI template to automatically splice together a test report containing tumor markers, genetic mutations, and other content. The report is printed with the name 'MEDVi Laboratory' and a fabricated doctor's signature, but lacks any laboratory qualification number. Because patients cannot read the indicators, the forgery is difficult to detect.
• Sending reports and secondary sales: The fake reports are sent via regular email or PDF, accompanied by an 'AI doctor interpretation' claiming to have found 'early cancer signals' and recommending the purchase of expensive 'targeted nutrient' or 'cell therapy' packages. Some patients end up paying a third time, with amounts ranging from hundreds to tens of thousands of dollars, forming a closed-loop scam cycle of 'testing—reporting—treatment.'
• Disappearance and rebranding: When patients take the reports to regular hospitals for review, discover anomalies, or file official complaints, the company stalls with excuses like 'data encryption' or 'testing batch error,' then cancels the original brand and relaunches under a new alias. Reports indicate that a single individual played multiple corporate roles within this company, continuously harvesting new victims by constantly changing website domains and company names.

红旗信号（看到这些快跑）

• 🚩 Emphasizing 'AI' and 'precision' in promotion while refusing to provide any testing equipment registration numbers or FDA approval numbers.
• 🚩 Requiring detailed medical history and identity documents to be filled out, but failing to present Clinical Laboratory Improvement Amendments (CLIA) certification.
• 🚩 The cover page of the report lacks a laboratory address, contact phone number, and the medical director's name, featuring only a blurred logo.
• 🚩 Payment channels consist of personal accounts, cryptocurrency, or wire transfers, with point-of-sale (POS) machines and formal invoices rejected.
• 🚩 Using high-urgency sales pitches like 'last batch of testing slots' and 'discount limited to today,' while arranging for 'customer service doctors' to apply continuous pressure.

真实案例

• In April 2026, the US FDA issued a warning letter to MEDVi, pointing out that its AI advertising claims of 'diagnosing cancer' were misleading statements and misbranded, and the company faced class-action lawsuits filed by victims across multiple states. The company had previously claimed a valuation of $12 billion before collapsing after the scam was exposed.
• In April 2026, The New York Times reported that the company, which claimed to be a '$1 billion one-person company,' was actually operated entirely by founder A. *[transliteration/placeholder]* impersonating multiple departments and using AI to generate fake papers and data to trick investors and patients. The report caused a public outcry, and the company was subsequently shut down for investigation. (Source: [https://www.163.com/dy/article/KPTHL35R051181RS.html](https://www.163.com/dy/article/KPTHL35R051181RS.html))
• In April 2026, a media investigation revealed that behind MEDVi lay a gray pharmaceutical supply chain, with multiple patients who purchased 'AI testing' services receiving templated fake reports where the so-called 'expert signatures' were verified as non-existent. One patient delayed formal cancer screening for nearly half a year due to blindly trusting the 'low risk' conclusion in the fake report.
• In July 2022, the US Department of Justice announced criminal charges against 36 defendants, accusing them of healthcare fraud through telemedicine and cancer genetic testing, involving more than $1.2 billion. The case spanned 13 federal judicial districts across the United States, involving entities such as telemedicine companies and testing laboratories that lured patients with false cancer screenings. (Source: [https://natlawreview.com/article/dozens-charged-12-billion-nationwide-telemedicine-and-dme-fraud-scheme](https://natlawreview.com/article/dozens-charged-12-billion-nationwide-telemedicine-and-dme-fraud-scheme))
• In September 2019, the US Department of Justice announced criminal charges against 35 defendants, involving dozens of telemedicine companies and cancer genetic testing laboratories that fraudulently billed Medicare over $2.1 billion for cancer genetic testing, marking one of the largest healthcare fraud cases in US history at the time. (Source: [https://kffhealthnews.org/morning-breakout/doj-brings-charges-against-35-people-in-2-1b-medicare-genetic-cancer-test-scam/](https://kffhealthnews.org/morning-breakout/doj-brings-charges-against-35-people-in-2-1b-medicare-genetic-cancer-test-scam/))

Official Stance

• In April 2026, the US FDA issued a warning letter to MEDVi, explicitly stating that its cancer testing advertisements violated the Federal Food, Drug, and Cosmetic Act.
• In April 2026, the US FDA and the US Federal Trade Commission (FTC) jointly issued a consumer alert warning the public against false advertising related to 'AI cancer diagnosis.'
• In April 2026, the official US FDA website published the archive of the aforementioned warning letter along with a media statement announcing that it would further pursue the liability of the relevant entities.

How to Protect Yourself

• ✅ Search the FDA CDRH database on its official website to check whether the testing item holds 510(k) or PMA clearance.
• ✅ Ask the provider to supply their CLIA certification number, and visit the US CDC website to verify whether the number is authentic and valid.
• ✅ Insist on paying with a credit card so that chargebacks can be initiated through the card issuer if fraud is discovered.
• ✅ After receiving a test report, take it to a tertiary hospital or independent laboratory for a verification check rather than directly trusting 'AI conclusions.'
• ✅ If you have already been scammed, immediately file a complaint with the FDA, the FTC, and your state attorney general's office, while keeping chat logs, payment receipts, and the original report.